Actively Recruiting
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Led by Samsung Medical Center · Updated on 2024-06-12
92
Participants Needed
1
Research Sites
478 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.
CONDITIONS
Official Title
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed endometrioid type endometrial cancer
- Completion of hysterectomy and surgical staging
- Pathologically confirmed FIGO stage III
- ECOG performance status of 0 or 1
- Adjuvant chemotherapy completed or planned
You will not qualify if you...
- Presence of distant metastasis
- Previous history of pelvic radiotherapy
- Severe and unstable medical condition
- Previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
W
Won Park
CONTACT
W
Won Kyung Cho
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here